John W Stevens

List of Publications by Year
in descending order

60 papers	2,307 citations	212478 28 h-index	252626 46 g-index
61 all docs	61 docs citations	61 times ranked	3530 citing authors

#	Article	IF	Citations
1	Worldwide relative smoking prevalence among people living with and without HIV. Aids, 2021, 35, 957-970.	1.0	32
2	Prevalence of respiratory conditions among people who use illicit opioids: a systematic review. Addiction, 2020, 115, 832-849.	1.7	25
3	Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network metaâ€anâ€alysis. Journal of Thrombosis and Haemostasis, 2020, 18, 422-438.	1.9	27
4	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. Pharmacoeconomics, 2020, 38, 193-204.	1.7	25
5	Reply to Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. Journal of Thrombosis and Haemostasis, 2020, 18, 519-520.	1.9	0
6	Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). Emergency Medicine Journal, 2020, 37, 36-41.	0.4	25
7	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making, 2019, 39, 899-909.	1.2	28
8	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. Pharmacoeconomics, 2019, 37, 1537-1551.	1.7	12
9	Decisionâ€anâ€alysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 2019, 186, 166-168.	1.2	1
10	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1639-1644.	2.1	4
11	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 2019, 23, 1-328.	1.3	35
12	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-190.	1.3	17
13	Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. Medical Decision Making, 2018, 38, 531-542.	1.2	14
14	Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 1143-1151.	1.7	0
15	A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. Research Synthesis Methods, 2018, 9, 148-162.	4.2	19
16	Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?. Pharmacoeconomics, 2018, 36, 1135-1141.	1.7	2
17	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technology Assessment, 2018, 22, 1-294.	1.3	16
18	Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 2017, 37, 377-390.	1.2	79

#	Article	IF	Citations
19	Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 805-815.	1.7	8
20	A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. Pharmacoeconomics, 2016, 34, 1023-1038.	1.7	21
21	Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone, 2016, 89, 52-58.	1.4	59
22	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment, 2016, 20, 1-326.	1.3	41
23	A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 2016, 20, 1-406.	1.3	62
24	Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 2015, 107, 320-331.	1.1	112
25	Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2015, 33, 833-847.	1.7	27
26	Systematic review and economic modelling of the clinical effectiveness and cost-effectiveness of art therapy among people with non-psychotic mental health disorders. Health Technology Assessment, 2015, 19, 1-120.	1.3	71
27	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 2015, 19, 1-102.	1.3	43
28	Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Metaâ€analysis, and Individual Patient Data Metaâ€analysis. Academic Emergency Medicine, 2014, 21, 960-970.	0.8	52
29	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. Angiology, 2014, 65, 190-197.	0.8	18
30	Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-176.	1.3	34
31	The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment, 2014, 18, 1-168.	1.3	30
32	What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-120.	1.3	60
33	Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. Emergency Medicine Journal, 2013, 30, 280-286.	0.4	40
34	Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 653-661.	1.7	18
35	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart, 2013, 99, 1717-1726.	1.2	114
36	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open, 2013, 3, e003250.	0.8	41

#	Article	IF	Citations
37	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 2012, 98, 1498-1503.	1.2	40
38	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery, 2012, 99, 1630-1638.	0.1	94
39	Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality. PLoS ONE, 2012, 7, e30711.	1.1	49
40	Uncertainty analysis is inherently Bayesian. Value in Health, 2011, 14, 202-203.	0.1	1
41	A note on dealing with missing standard errors in metaâ€analyses of continuous outcome measures in WinBUGS. Pharmaceutical Statistics, 2011, 10, 374-378.	0.7	23
42	Pharmaceutical Statistics 10th anniversary. Pharmaceutical Statistics, 2011, 10, 475-476.	0.7	0
43	NICE work: how NICE decides what we should pay for. British Journal of General Practice, 2010, 60, 7-8.	0.7	4
44	Using shortâ€term evidence to predict sixâ€month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. Pharmaceutical Statistics, 2009, 8, 150-162.	0.7	8
45	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharmaceutical Statistics, 2009, 8, 371-389.	0.7	16
46	Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Statistics in Medicine, 2006, 25, 37-53.	0.8	37
47	Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharmaceutical Statistics, 2006, 5, 125-133.	0.7	38
48	Assurance in clinical trial design. Pharmaceutical Statistics, 2005, 4, 187-201.	0.7	211
49	An Evaluation of a Bayesian Method of Dose Escalation Based on Bivariate Binary Responses. Journal of Biopharmaceutical Statistics, 2004, 14, 969-983.	0.4	24
50	On estimators of medical costs with censored data. Journal of Health Economics, 2004, 23, 615-625.	1.3	60
51	Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?. Health Economics (United Kingdom), 2003, 12, 33-49.	0.8	83
52	Case study in the Bayesian analysis of a cost-effectiveness trial in the evaluation of health care technologies: Depression. Pharmaceutical Statistics, 2003, 2, 51-68.	0.7	9
53	Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies. Statistical Methods in Medical Research, 2002, 11, 469-490.	0.7	55
54	INCORPORATION OF GENUINE PRIOR INFORMATION IN COST-EFFECTIVENESS ANALYSIS OF CLINICAL TRIAL DATA. International Journal of Technology Assessment in Health Care, 2002, 18, 782-790.	0.2	14

#	Article	IF	Citations
55	Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. Epilepsy and Behavior, 2002, 3, 140-146.	0.9	37
56	Remacemide versus carbamazepine in newly diagnosed epilepsy. Epilepsy and Behavior, 2002, 3, 405-406.	0.9	3
57	The probability of cost-effectiveness. BMC Medical Research Methodology, 2002, 2, 5.	1.4	39
58	Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine, 2001, 20, 733-753.	0.8	87
59	A framework for cost-effectiveness analysis from clinical trial data. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.8	82
60	Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio. Pharmacoeconomics, 2000, 17, 339-349.	1.7	78